URCC NCORP Research Base

URCC NCORP研究基地

• 批准号: 10247205
• 负责人: KAREN M. MUSTIAN
• 金额: $ 75.7万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-01 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10247205
• 关键词: Achievement; Age; American Society of Clinical Oncology; Award; Behavioral; Biological; Biological Markers; Cancer Center; Cancer Control; Cancer Control Research; Cancer Patient; Cancer Survivor; Caregivers; Caring; Clinic; Clinical; Clinical Cancer Center; Clinical Oncology; Clinical Research; Clinical Research Associate; Clinical Trials; Cluster randomized trial; Collection; Committee Members; Communities; Community Clinical Oncology Program; Community Networks; Conduct Clinical Trials; Data; Development; Enrollment; Epigenetic Process; Ethics; Ethnic Origin; Etiology; Funding; Gender; Goals; Grant; Immunologics; Immunotherapy; Individual; Innovative Therapy; Institutes; Intervention; Journals; Knowledge; Leadership; Malignant Neoplasms; Manuscripts; Medical Oncologist; Mentors; Minority; Modernization; Morbidity - disease rate; NCI Center for Cancer Research; National Cancer Institute; Nature; Nurses; Oncologist; Oncology; Operative Surgical Procedures; Outcome; Pathway interactions; Patient Care; Patients; Peer Review; Phase; Physicians; Physiological; Pilot Projects; Positioning Attribute; Prevalence; Procedures; Productivity; Program Development; Prospective cohort study; Protocols documentation; Publications; Publishing; Quality of Care; Race; Radiation Oncologist; Radiation therapy; Randomized; Randomized Clinical Trials; Reporting; Research; Research Personnel; Resources; Risk; Scientific Inquiry; Severities; Sex Orientation; Site; Supportive care; Surgeon; Survivors; Symptoms; System; Testing; Time; Toxic effect; Training; Treatment Side Effects; Underserved Population; United States; Universities; Vision; Woman; Work; anticancer research; base; cancer care; cancer therapy; care delivery; chemotherapy; clinical care; data acquisition; design; experience; gene therapy; health disparity; health equity; hormone therapy; human subject protection; improved; innovation; investigator training; member; novel; programs; psychosocial; recruit; side effect; stem; symptom science; system-level barriers; treatment guidelines; virtual

ABSTRACT: The University of Rochester Cancer Center (URCC) National Cancer Institute Community Oncology Research Program (NCORP) Research Base (RB) is a RB with 35+ years of experience conducting cancer control research (CCR) and cancer care delivery research (CCDR). The URCC NCORP RB’s vision is "to help good people through lousy times when they experience cancer” by reducing cancer- and treatment- related morbidity stemming from toxicities and side effects. Since 2014, 35% (N=2,831) of all NCORP accrual credits resulted from enrollment of patients and survivors by our Community Affiliates on our 13 active URCC clinical trials. URCC and its Community Affiliates also enrolled 421 caregivers and more than 300 oncologists to our 13 active trials, as well as 1,752 patients and survivors to our 29 local pilot studies. URCC successfully enrolled and randomized over 30 individual community oncology practices to cluster randomized trials. Our investigators and staff submitted 8 new concepts/grants, with 18 new concepts/grants currently in development, and 29 active pilot studies. The significant and innovative contribution of URCC research to scientific knowledge and clinical care is evidenced by 1) 197 published manuscripts, 2) 209 presented abstracts, 3) 25 podium presentations at ASCO, 4) 82 outstanding research awards to our investigators, 5) 12 junior investigators successfully trained to conduct research in NCORP, and 6) 2,215 investigators, clinicians, and staff successfully trained to implement URCC NCORP RB protocols at community sites across the United States. Notable recognition of the significance of research conducted by the URCC RB and its investigators includes: 1) Best of JCO publication for 2017, 2) most cited article in JAMA Oncology for 2017, 3) one of the most significant advances in cancer research and care for 2018, 4) citation of our published research in virtually all existing supportive care treatment guidelines, and 5) leadership by 5 of our RB Executive Committee members in the development of 4 supportive care treatment guidelines. We accomplish our goal of reducing cancer- and treatment-related morbidity by working with cancer patients, survivors, and their caregivers from 592 community oncology practices across the United States to design and conduct CCR and CCDR, including translational and health equity outcomes, focused in symptom science. Our research develops and tests novel treatments for toxicities and side effects stemming from cancer and its treatments. We design and conduct phase I-III randomized clinical trials and longitudinal, prospective cohort studies. To meet its responsibilities as a RB and maintain its high level of productivity over the next funding period, the URCC RB will focus its resources and expertise on the following specific aims: Aim 1) to conduct CCR, Aim 2) to conduct CCDR, Aim 3) to conduct translational CCR, Aim 4) to conduct health equity CCR and CCDR, and Aim 5) to provide state-of-the-art training and mentoring for NCORP investigators and staff. With its proven track record of productivity and innovation, the URCC NCORP RB is expertly positioned to continue its pioneering symptom science research in the NCORP Network.

摘要：罗切斯特大学癌症中心（URCC）国家癌症研究所社区 肿瘤研究计划（NCORP）研究基础（RB）是RB，具有35年以上的经验 癌症控制研究（CCR）和癌症护理递送研究（CCDR）。 URCC NCORP RB的愿景是 “通过减少癌症和治疗 - 毒性和副作用引起的相关发病率。自2014年以来，所有NCORP Accral中有35％（n = 2,831） 我们的社区分支机构在我们的13个活跃的URCC上招募了患者和幸存者的信用。 临床试验。 URCC及其社区分支机构还招募了421位护理人员和300多名肿瘤学家 我们的13次主动试验以及1,752例患者和29例本地试点研究的生存。成功 招募和随机分配了30多个个人社区肿瘤学实践，以聚集随机试验。我们的 调查人员和工作人员提交了8个新概念/赠款，目前正在开发18个新概念/赠款， 和29项主动试点研究。 URCC研究对科学知识的重大和创新贡献 1）197 197个手稿，2）209摘要，3）25个领奖台 在ASCO上的演讲，4）82个杰出研究奖，我们的研究人员5）12个初级调查人员 经过成功在NCORP进行研究的培训，6）2,215名调查员，临床医生和员工成功地 经过培训，可以在美国各地的社区站点实施URCC NCORP RB协议。值得注意的 认识到URCC RB及其研究者进行的研究意义的认识包括：1）最佳 2017年的JCO出版物，2）2017年JAMA肿瘤学中最引用的文章，3）最重要的进步之一 在2018年的癌症研究和护理方面，4）引用我们几乎所有现有的支持护理中发表的研究 治疗指南和5）我们的RB执行委员会成员的领导能力4 支持护理治疗指南。我们实现了减少癌症和治疗相关的目标 通过与592个社区肿瘤习惯的癌症患者，幸存者及其护理人员合作而发病 在整个美国设计和进行CCR和CCDR，包括转化和健康公平 结果，专注于症状科学。我们的研究发展和测试了有关毒性和 癌症及其治疗的副作用。我们设计和进行I-III期随机临床 试验和纵向，前瞻性队列研究。满足RB的责任并保持高水平 在下一个资金期间的生产力，URCC RB将把其资源和专业知识集中在以下 具体目的：目标1）进行CCR，目标2）进行CCDR，目标3）进行翻译CCR，目标4） 进行健康权益CCR和CCDR，目标5）为提供最先进的培训和心理 NCORP调查人员和工作人员。凭借其可靠的生产力和创新记录，URCC NCORP RB在NCORP网络中继续保持其开创性的症状科学研究。